Form 4: Atossa Therapeutics Director Chen Shu-Chih Acquires Stock Options

Director Chen Shu-Chih of Atossa Therapeutics acquired stock options for 125,000 shares on May 15, 2025.

Summary

• On May 15, 2025, Chen Shu-Chih, a director of Atossa Therapeutics, acquired stock options for 125,000 shares.
• The exercise price of these options is $0.99 per share, which was the closing stock price on the grant date.
• The options vest quarterly over 12 months, contingent upon continued service.
• The options expire on May 15, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a routine event, but it can signal confidence from the director in the company's future.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock options are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology sector. They align the interests of management with those of shareholders by incentivizing them to increase the company's stock price.

Stakeholder Impact

• The granting of stock options could potentially impact shareholders positively if the director's actions lead to an increase in the company's stock price.

Key Dates

Keywords

stock options, director, Atossa Therapeutics, Chen Shu-Chih, Form 4, insider trading